Antibody framework residues affecting the conformation of the hypervariable loops.
暂无分享,去创建一个
G. Winter | J. Foote | G Winter | J Foote | Greg Winter
[1] C. Milstein,et al. Reshaping human antibodies: grafting an antilysozyme activity. , 1988, Science.
[2] G Scalise,et al. Letter: Australia antigen in urine. , 1973, Lancet.
[3] A Tramontano,et al. Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. , 1990, Journal of molecular biology.
[4] V. Pascual,et al. Human immunoglobulin heavy-chain variable region genes: organization, polymorphism, and expression. , 1991, Advances in immunology.
[5] P. T. Jones,et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.
[6] K. R. Ely,et al. Structure of a lambda-type Bence-Jones protein at 3.5-A resolution. , 1972, Biochemistry.
[7] E. Kabat,et al. ATTEMPTS TO LOCATE COMPLEMENTARITY‐DETERMINING RESIDUES IN THE VARIABLE POSITIONS OF LIGHT AND HEAVY CHAINS * , 1971, Annals of the New York Academy of Sciences.
[8] E. Padlan,et al. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. , 1991, Molecular immunology.
[9] M. Neuberger,et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies , 1987, The Journal of experimental medicine.
[10] C. Milstein,et al. [1] Preparation of monoclonal antibodies: Strategies and procedures , 1981 .
[11] T. Bhat,et al. Crystallographic refinement of the three-dimensional structure of the FabD1.3-lysozyme complex at 2.5-A resolution. , 1991, The Journal of biological chemistry.
[12] R. Mulligan,et al. Expression of a bacterial gene in mammalian cells. , 1980, Science.
[13] E. Unanue,et al. Specificity of the T cell receptor: two different determinants are generated by the same peptide and the I-Ak molecule. , 1985, Journal of immunology.
[14] M. Smith,et al. Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA. , 1982, Nucleic acids research.
[15] E. Getzoff,et al. Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[16] T. N. Bhat,et al. Small rearrangements in structures of Fv and Fab fragments of antibody D 1.3 on antigen binding , 1990, Nature.
[17] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[18] Lutz Riechmann,et al. Reshaping human antibodies for therapy , 1988, Nature.
[19] A. Bothwell,et al. A limited number of B cell lineages generates the heterogeneity of a secondary immune response. , 1987, Journal of immunology.
[20] P. Leder,et al. Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[21] R. Poljak,et al. Antigen specificity and cross-reactivity of monoclonal anti-lysozyme antibodies. , 1987, Molecular immunology.
[22] J. A. Rupley,et al. Fluorescence of lysozyme: emissions from tryptophan residues 62 and 108 and energy migration. , 1972, Proceedings of the National Academy of Sciences of the United States of America.
[23] C. Yanisch-Perron,et al. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. , 1985, Gene.
[24] T. Honjo,et al. Structure of human immunoglobulin gamma genes: implications for evolution of a gene family , 1982, Cell.
[25] G. Air,et al. Crystal structures of neuraminidase-antibody complexes. , 1989, Cold Spring Harbor symposia on quantitative biology.
[26] G. Cohen,et al. The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[27] B. L. Duuren. Solvent Effects in the Fluorescence of Indole and Substituted Indoles1 , 1961 .
[28] G. Hale,et al. Monoclonal-antibody therapy in systemic vasculitis. , 1990, The New England journal of medicine.
[29] G Goldstein,et al. The complete amino acid sequence of ubiquitin, an adenylate cyclase stimulating polypeptide probably universal in living cells. , 1975, Biochemistry.
[30] M. Neuberger. Expression and regulation of immunoglobulin heavy chain gene transfected into lymphoid cells. , 1983, The EMBO journal.
[31] R. Lathe,et al. New versatile cloning and sequencing vectors based on bacteriophage M13. , 1983, Gene.
[32] A. Lesk,et al. Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.
[33] E. Haber,et al. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[34] R. Bruccoleri,et al. Computer analysis of mutations that affect antibody specificity , 1990, Proteins.
[35] T. T. Wu,et al. AN ANALYSIS OF THE SEQUENCES OF THE VARIABLE REGIONS OF BENCE JONES PROTEINS AND MYELOMA LIGHT CHAINS AND THEIR IMPLICATIONS FOR ANTIBODY COMPLEMENTARITY , 1970, The Journal of experimental medicine.
[36] A. Ciechanover,et al. Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. , 1980, The Journal of biological chemistry.
[37] G. M. Griffiths,et al. Molecular events during maturation of the immune response to oxazolone , 1985, Nature.
[38] G. Winter,et al. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[39] J. Vieira,et al. The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. , 1982, Gene.
[40] R. Poljak,et al. Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution , 1986, Science.
[41] M. Neuberger,et al. A hapten-specific chimaeric IgE antibody with human physiological effector function , 1985, Nature.
[42] C. Milstein,et al. Three‐dimensional structure determination of an anti‐2‐phenyloxazolone antibody: the role of somatic mutation and heavy/light chain pairing in the maturation of an immune response. , 1990, The EMBO journal.
[43] H. Waldmann,et al. REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H , 1988, The Lancet.
[44] D. Allen,et al. Antibody engineering for the analysis of affinity maturation of an anti‐hapten response. , 1988, The EMBO journal.
[45] J. Maizel,et al. Evolution of human immunoglobulin kappa J region genes. , 1982, The Journal of biological chemistry.
[46] M Levitt,et al. A humanized antibody that binds to the interleukin 2 receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[47] Geraldine Taylor,et al. Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo , 1991, Bio/Technology.
[48] R. Poljak,et al. Three-dimensional structure of the Fab' fragment of a human immunoglobulin at 2,8-A resolution. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[49] C. Milstein,et al. Somatic mutation and the maturation of immune response to 2-phenyl oxazolone , 1984, Nature.
[50] H. Zachau,et al. Correct transcription of an immunoglobulin κ gene requires an upstream fragment containing conserved sequence elements , 1984, Nature.
[51] J Saldanha,et al. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. , 1991, Protein engineering.
[52] S. Levy,et al. Hybridoma fusion cell lines contain an aberrant kappa transcript. , 1988, Molecular immunology.
[53] D. Ish-Horowicz,et al. Rapid and efficient cosmid cloning , 1981, Nucleic Acids Res..
[54] R. Huber,et al. Crystal and molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI. , 1974, European journal of biochemistry.
[55] R. Whitley,et al. Humanized antibodies for antiviral therapy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[56] H. Waldmann,et al. Reshaping a therapeutic CD4 antibody. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[57] S. Matsushita,et al. Construction of reshaped human antibodies with HIV-neutralizing activity. , 1991, Human antibodies and hybridomas.